These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32528828)

  • 1. Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells
    Zeng F; Wang F; Zheng Z; Chen Z; Wah To KK; Zhang H; Han Q; Fu L
    Acta Pharm Sin B; 2020 May; 10(5):799-811. PubMed ID: 32528828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2
    Zhang Z; Guo X; To KKW; Chen Z; Fang X; Luo M; Ma C; Xu J; Yan S; Fu L
    Acta Pharm Sin B; 2018 Jul; 8(4):563-574. PubMed ID: 30109181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
    Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
    Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo.
    Chen Z; Chen Y; Xu M; Chen L; Zhang X; To KK; Zhao H; Wang F; Xia Z; Chen X; Fu L
    Mol Cancer Ther; 2016 Aug; 15(8):1845-58. PubMed ID: 27196753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2.
    Xu L; Huang J; Liu J; Xi Y; Zheng Z; To KKW; Chen Z; Wang F; Zhang Y; Fu L
    Mol Ther Oncolytics; 2020 Mar; 16():100-110. PubMed ID: 32055675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells i
    Fan Y; Tao T; Guo Z; Wah To KK; Chen D; Wu S; Yang C; Li J; Luo M; Wang F; Fu L
    Mol Ther Oncolytics; 2022 Mar; 24():636-649. PubMed ID: 35284628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo.
    Yang K; Chen Y; To KK; Wang F; Li D; Chen L; Fu L
    Exp Mol Med; 2017 Mar; 49(3):e303. PubMed ID: 28303028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.
    Mi YJ; Liang YJ; Huang HB; Zhao HY; Wu CP; Wang F; Tao LY; Zhang CZ; Dai CL; Tiwari AK; Ma XX; To KK; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2010 Oct; 70(20):7981-91. PubMed ID: 20876799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo.
    Zhang Y; Li C; Xia C; Wah To KK; Guo Z; Ren C; Wen L; Wang F; Fu L; Liao N
    Cell Commun Signal; 2022 Sep; 20(1):142. PubMed ID: 36104708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells.
    Zhang W; Fan YF; Cai CY; Wang JQ; Teng QX; Lei ZN; Zeng L; Gupta P; Chen ZS
    Front Pharmacol; 2018; 9():1097. PubMed ID: 30356705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
    Shi Z; Tiwari AK; Shukla S; Robey RW; Kim IW; Parmar S; Bates SE; Si QS; Goldblatt CS; Abraham I; Fu LW; Ambudkar SV; Chen ZS
    Biochem Pharmacol; 2009 Mar; 77(5):781-93. PubMed ID: 19059384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters.
    Nazari S; Mosaffa F; Poustforoosh A; Mortazavi M; Saso L; Firuzi O; Moosavi F
    Toxicol Appl Pharmacol; 2024 Mar; 484():116866. PubMed ID: 38367674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
    Yang L; Li M; Wang F; Zhen C; Luo M; Fang X; Zhang H; Zhang J; Li Q; Fu L
    Cell Physiol Biochem; 2018; 46(6):2487-2499. PubMed ID: 29742496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.
    Sodani K; Patel A; Anreddy N; Singh S; Yang DH; Kathawala RJ; Kumar P; Talele TT; Chen ZS
    Biochem Pharmacol; 2014 May; 89(1):52-61. PubMed ID: 24565910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.